DAWSONJAMES SECURITIES

INSTITUTIONAL RESEARCH

Emerging GrowthUPDATE REPORT

Member FINRA/SIPC

Toll-Free: 866-928-0928 • www.DawsonJames.com • 101 North Federal Highway - Suite 600 • Boca Raton, FL 33432

Better Choice Company Inc. (NYSE AM: BTTR)

August 12, 2022

Buy: Q2 Review.

Q2 revenue was better than expected but margins were impacted by one-time launch costs. The second half will be lower as the U. S. specialty store and international channels absorb product delivered in the first half. We expect strong growth and margin improvement next year. We reiterate our \$10 target based on an EV/sales multiple of 4x our 2023 sales estimate.

Q2 revenue of \$16.5 million exceeded our \$16.2 million estimate and consensus of \$15.5 million. Excluding launch costs of Halo Elevate gross margin of 32% exceeded our estimate and excluding the launch costs and re-branding expenses, totaling about \$1 million, EBITDA would have also exceeded our estimates.

International sales for the quarter were \$7.1 million and \$14 million for the first half. This is almost equal to the full-year sales to the international markets in 2021. Part of the increase in the first half relates to company efforts to anticipate supply-chain challenges and have product available in the market for the important Singles Day in China. This pulled forward sales from the second half. We continue to expect the company to generate about \$25 million in sales in the international market this year, but first-half loaded instead of our prior expectation of a second-half load.

Sales to the Brick & Mortar channel were \$4 million for the quarter, \$8.3 million for the first half and up 130% over the first half of 2021. The company's roll-out to PetCo and Pet Supplies Plus has progressed faster than we previously modeled and resulted in better sales than we had forecast in the first half but the second half will be lower as the channel adjusts to the initial inventory fill.

Reported gross margin for the quarter was 29% versus 28% in Q1. Excluding Halo Elevate launch costs gross margin would have been 32% and a new manufacturing partner for international product will result in further gross margin improvement in the second half. We have modeled gross margin of 34.5% in the second half and improving to 36% next year.

We reiterate our Buy recommendation and \$10 price target. The company is in the early stages of expansion in the U.S. brick and mortar segment, is on track to exceed its \$100 million in aggregate contract minimums through 2025 from international distributors and has completed the integration of its TruDog brand into the Halo product portfolio. The shares have been buffeted by the decline in small-cap stocks and offer substantial value at current levels.

James McIlree, CFA 561-237-2709 jmcilree@dawsonjames.com

| | | | U | | |
|-------|--|--|---|---|--|
| | | | | | \$2.45 |
| | | | | | \$10.00 |
| F | 2021A | | F2022E | F | 2023E |
| \$ | 46,006 | \$ | 61,710 E | \$ | 80,349 |
| \$ | 10,830 | \$ | 17,014 A | \$ | 20,054 |
| \$ | 10,989 | \$ | 16,515 A | \$ | 20,795 |
| \$ | 13,200 | \$ | 13,481 E | \$ | 19,375 |
| \$ | 10,987 | \$ | 14,700 E | \$ | 20,125 |
| F | 2021A | | F2022E | F | 2023E |
| \$ | (11,475) | \$ | (11,276)E | \$ | (3,090) |
| \$ | (2,183) | \$ | (2,461)A | \$ | (1,084) |
| \$ | (2,471) | \$ | | | (617) |
| \$ | (2,876) | \$ | (3,173)E | \$ | (934) |
| \$ | (3,945) | \$ | (2,612)E | \$ | (455) |
| | | | | | |
| | 1.4 x | | 1.1 x | | 0.8 x |
| | (5.8) x | | (5.9) x | | (21.5) x |
| | | | | | |
| | \$1.70 | | - | | \$4.30 |
| | | | | | 29.4 |
| .) | | | | | \$72 |
| | | | | | \$67 |
| | | | | | 19% |
| | | | | | \$18 |
| | | | | | \$0.61 |
| adir | ng Volum | ne | (K) | | 16 |
| | .8 | | , | | 35.8% |
| | | | | | 33.4% |
| | | _ | | _ | 0.6% |
| _ | | _ | | ٠٠، | 0.0% |
| | | | | 0.0 | 00/0.0% |
| any | , Inc. (B | TT | | | 100) |
| | | | Pric | e (U | 4.5 |
| | | | | | -4 |
| | ΔÅ | | | | |
| | N | | | | - 3.5 |
| \ | 11 | | | | -3 |
| ٧ | 1 1 | . 1 | ard | | |
| 1 |) NM | ~ | 1000 | | ₩-2.5 |
| | | | M | he | / 1-2 |
| | A. Jane | | | V | |
| Jan | Feb Mar | | or May Jun | Ju | 1.5 I |
| noice | Company, | Inc. | | 210 | at Drives |
| | \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ | \$ 10,830 \$ 10,989 \$ 13,200 \$ 10,987 F2021A \$ (11,475) \$ (2,1876) \$ (2,876) \$ (2,876) \$ (3,945) 1.4 x \$1.70 | \$ 46,006 \$ \$ 10,830 \$ \$ 10,830 \$ \$ 10,987 \$ \$ 13,200 \$ \$ 13,200 \$ \$ 10,987 \$ F2021A \$ (11,475) \$ \$ (2,876) \$ \$ (2,876) \$ \$ (3,945) \$ 1.4 x (5.8) x \$ 1.70 | \$ 46,006 \$ 61,710 E \$ 10,830 \$ 17,014 A \$ 10,989 \$ 16,515 A \$ 13,200 \$ 13,481 E \$ 10,987 \$ 14,700 E FO21A \$ 2022E \$ (11,475) \$ (11,276)E \$ (2,183) \$ (2,461)A \$ (2,471) \$ (3,030)A \$ (2,876) \$ (3,173)E \$ (3,945) \$ (2,612)E | \$ 46,006 \$ 61,710 E \$ \$ 10,830 \$ 17,701 A \$ \$ 10,989 \$ 16,515 A \$ \$ 13,200 \$ 13,481 E \$ \$ 10,987 \$ 14,700 E \$ F2021A F2022E F \$ (11,475) \$ (11,276)E \$ \$ (2,183) \$ (2,461)A \$ \$ (2,471) \$ (3,030)A \$ \$ (2,876) \$ (3,173)E \$ \$ (3,945) \$ (2,612)E \$ 1.4 x |

Valuation: An EV/Sales multiple of 4x applied to our 2023 revenue estimate results in a price target range of \$10 to \$12 per share. The low end of the range assumes exercise of the company's warrants. Our \$10 price target uses the 4x EV/Sales multiple and assumes exercise of the company's warrants.

Risks: Risks to achieving our price target include an interruption in the economic recovery, less expansion in the domestic retail channel than we project, Asian distributors not meeting their minimum purchase obligations, cost increases impacting margins and greater time and resources needed to meet sales objectives.



Cash at quarter end was \$17.8 million (including \$7 million in restricted cash required by the company's credit facility), and for the quarter operating cash flow consumed \$5.3 million of cash. A significant part of the cash use was for inventory, which increased \$2.2 million from Q1. The company has invested in inventory to support the Halo Elevate launch and to anticipate supply chain disruptions. We expect inventory to decline as the Halo Elevate launch matures, but to remain higher than desired until normalcy returns to the supply chain.

We believe cash is adequate for the company's growth plans but the margin for unexpected issues or opportunities is less than we prefer.

Actual v Estimates

| Q2 22 | | | | | | | |
|------------------------|-------|---------|-----|----------------|-------|-------|---------|
| (\$ in 000's) | | | | | | | |
| | Actua | l | Est | imates | Delta | | % Delta |
| Revenue | \$ | 16,515 | \$ | 16,234 | \$ | 281 | 2% |
| COGS | | 11,788 | | 11,201 | | | |
| Gross Profit | | 4,727 | | 5,033 | | (306) | -6% |
| Gross margin | | 28.6% | | 31.0% | | | |
| Sales and marketing | | 8,187 | | 7,577 | | | |
| Other | | 801 | | 1,091 | | | |
| Opex | | 8,988 | | 8,668 | | | |
| Operating Income | \$ | (4,261) | \$ | (3,635) | \$ | (626) | -15% |
| Interest Expense | | 106 | | 76 | | | |
| Pretax Income | \$ | (4,367) | \$ | (3,711) | | | |
| Taxes | | 0 | | 0 | | | |
| Net to common | \$ | (4,367) | \$ | (3,711) | | | |
| Diluted Shares | | 29,365 | | 29,365 | | | |
| Diluted EPS | \$ | (0.15) | \$ | (0.13) | | | |
| Depreciation and Amort | | 430 | | 413 | | | |
| Stock Comp | | 801 | | 1,091 | | | |
| EBITDA | \$ | (3,030) | \$ | (2,131) | \$ | (899) | -30% |
| Margin | | -18.3% | | -13.1% | | | |
| | | | | on Iamas Casur | | | |

Source: Better Choice and Dawson James Securities estimates

We have changed our estimates for this year and next to reflect the pace of the roll-out in the U.S. brick-and-mortar channel and the supply chain issues in the international markets. We have moderated the pace of margin improvement we had previously forecast, and this has resulted in lower EPS and EBITDA estimates for this year and next.



| | 202 | 2E | | 2023E | | | | | |
|------------------|--------------|-----|--------|-------|--------|-----|--------|--|--|
| | Old | New | Old | | | New | | | |
| Revenue (\$ M's) | \$ 65.1 | \$ | 61.7 | \$ | 83.3 | \$ | 80.3 | | |
| EPS | \$ (0.46) | \$ | (0.57) | \$ | (0.04) | \$ | (0.24) | | |
| EBITDA (\$ M's) | \$ (7.4) | \$ | (11.3) | \$ | 3.0 | \$ | (3.1) | | |
| | | | | | | | | | |

Source: Better Choice and Dawson James Securities estimates

The company's long-term financial model is a gross margin of 40% to 45%, contribution margin of 20% to 25% and long-term EBITDA margin of 10% to 15%. We believe the company is not likely to achieve these targets until 2024.

The company also has a goal of achieving \$100 million in gross annual sales within the next 3 years. This would equate to about \$85 million in net sales (gross sales less allowances and discounts), or a 25% CAGR from 2020. As mentioned above, higher growth is expected from the brick-and-mortar and international channels, with still strong growth from e-commerce and DTC.

We believe pet food sales will be less impacted than other major consumer expenditures by the Fed's tighter monetary policy. The pandemic has changed work-from-home habits for a generation and increased the number of pets and demand for pet food, particularly demand for premium food. We believe a mix shift to premium food is driven by the humanization of pets, greater time at home, lower birth rates and substantial cash balances on consumers' balance sheets.

We think the company has significant growth potential. Apart from the pet food market's two mega, mass-market suppliers, Nestlé's Purina and Mars which serve about 45% of the global pet food market, the rest of the market is highly fragmented. We believe this offers opportunities for well-managed and well-financed companies, such as Better Choice, to gain share organically and through acquisitions. We expect the pet food market will grow far in excess of nominal GDP growth in the U.S. driven by increased pet ownership, higher income, and migration to bigger houses on larger lots. The pandemic has boosted growth as more people work from home and have more opportunity to care for pets.

The company is led by an experienced and deep management team with a history of success in consumer products and pet food. Recent additions include experienced e-commerce and marketing talent. We also believe the company has the financial resources necessary to accomplish its goals, with over \$23 million in cash.

Valuation

Freshpet is the closest and most relevant comp to Better Choice. There are retailers in the pet business, but their margin and growth profiles are much different from Better Choice's. The pet food businesses of J.M. Smucker, General Mills, Colgate, Spectrum Brands and Nestlé are parts of larger businesses and have much lower expected growth relative to Better Choice.

| | | Price | | EPS | P/E | TEV | Sales | EV/ | EBITDA | EV/ |
|-----------|--|---------|-----|----------|---------|-------------|-------------|-------|----------|--------|
| | | | | | | (\$ M) | (\$ M) | Sales | (\$ M) | EBITDA |
| CHWY-US | Chewy, Inc. Class A | \$ 48.3 | 0 9 | 6 (0.23) | (208.3) | \$ 20,377.9 | \$ 11,025.4 | 1.85 | \$ 137.7 | 148.0 |
| ELAN-US | Elanco Animal Health, Inc. | 19.5 | 7 | 1.23 | 15.9 | 14,815.1 | 4,638.1 | 3.19 | 1,152.8 | 12.9 |
| FRPT-US | Freshpet Inc | 48.6 | 9 | (0.26) | (186.0) | 2,014.2 | 688.7 | 2.92 | 73.8 | 27.3 |
| BARK-US | BARK Inc Class A | 2.1 | 8 | (0.22) | (9.7) | 331.4 | 605.4 | 0.55 | (20.6) | (16.1) |
| WOOF-US | Petco Health & Wellness Company, Inc | 15.5 | 4 | 0.97 | 16.0 | 6,870.1 | 6,345.7 | 1.08 | 649.8 | 10.6 |
| PETQ-US | PetIQ, Inc. Class A | 14.9 | 7 | 1.34 | 11.1 | 893.5 | 971.5 | 0.92 | 102.1 | 8.7 |
| PETS-US | PetMed Express, Inc. | 22.2 | 5 | 0.98 | 22.7 | 359.3 | 276.4 | 1.30 | 26.9 | 13.4 |
| 300673-CN | Petpal Pet Nutrition Technology Co., Ltc | 16.7 | 8 | 0.74 | 22.6 | 4,285.2 | 1,939.3 | 2.21 | 314.7 | 13.6 |
| PET-CA | Pet Valu Holdings Ltd. | 34.9 | 0 | 1.59 | 21.9 | 3,051.3 | 966.3 | 3.16 | 216.6 | 14.1 |
| | Median | | | | 15.9 | | | 1.85 | | 13.4 |
| | Median-Retail | | | | 3.2 | | | 1.47 | | 12.3 |
| | Median-Products | | | | 15.9 | | | 2.21 | | 13.4 |
| BTTR-US | Better Choice Company, Inc. | \$ 2.4 | 5 5 | (0.37) | NM | \$ 57.0 | \$ 73.1 | 0.78 | \$ (6.3) | NM |


Source: FactSet and Dawson James Securities estimates

The chart below shows historical EV/Sales data for Freshpet, Blue Buffalo (while it was public) and Better Choice. Blue Buffalo had a similar growth, margin and market focus to Better Choice, so we believe its multiple history is relevant to where we believe Better Choice's shares could trade.



From August 2015 through March of 2018, the average EV/Sales based on forward-12-month sales estimates for Blue Buffalo was 4.0x. During this same period, Freshpet's shares traded at an average EV/Sales of 2.5x. From March 2018, when Blue Buffalo was acquired, through February 2020, when the pandemic began to have an impact on the market, Freshpet's shares traded at an average EV/Sales of 5.9x, and since March 2020 have traded at an average of 10.0x and currently trades at 3.5x FTM sales.

We believe the Blue Buffalo and Freshpet pre-pandemic average multiples are the most relevant for Better Choice's valuation. Growth is similar, as are margins. An EV/Sales multiple of 4x applied to our 2023 Better Choice revenue estimate results in a price target range of \$10 to \$12 per share. The low end of the range assumes exercise of the company's warrants. Our \$10 price target uses the 4x EV/Sales multiple and assumes exercise of the company's warrants.



Source: FactSet and Dawson James Securities estimates

Risk Analysis

Risks to achieving our price target include an interruption in the economic recovery, less expansion in the domestic retail channel than we project, Asian distributors not meeting their minimum purchase obligations, cost increases impacting margins and greater time and resources needed to meet sales objectives.



Exhibit 1. Income Statement

| (\$ in 000's) | 31-Dec-19 | 31-Dec-20 | 31-Dec-21 | 31-Mar-22 | 30-Jun-22 | 30-Sep-22 | 31-Dec-22 | 31-Dec-22 | 31-Dec-23 |
|---|------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| (except per share data) | 2019 A | 2020 A | 2021 A | Q1 22 A | Q2 22 A | Q3 22 E | Q4 22 E | 2022 E | 2023 E |
| Revenue | 15,577 | 42,590 | 46,006 | 17,014 | 16,515 | 13,481 | 14,700 | 61,710 | 80,349 |
| COGS | 9,717 | 26,485 | 30,638 | 12,307 | 11,788 | 8,897 | 9,555 | 42,547 | 51,027 |
| Gross Profit | 5,860 | 16,105 | 15,368 | 4,707 | 4,727 | 4,584 | 5,145 | 19,163 | 29,321 |
| Gross margin | 38% | 38% | 33% | 28% | 29% | 34% | 35% | 31% | 36% |
| SG&A | 34,487 | 34,487 | 28,507 | 7,577 | 8,187 | 8,187 | 8,187 | 32,138 | 34,058 |
| Share-based comp | 10,280 | 8,940 | 4,140 | 1,091 | 801 | 801 | 801 | 3,494 | 2,400 |
| Impairment | 889 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Opex | 45,656 | 43,427 | 32,647 | 8,668 | 8,988 | 8,988 | 8,988 | 35,632 | 36,458 |
| Operating Income | (39,796) | (27,322) | (17,279) | (3,961) | (4,261) | (4,404) | (3,843) | (16,469) | (7,137) |
| Interest Expense | 670 | 9,247 | 3,217 | 76 | 106 | 106 | 106 | 394 | 424 |
| Loss on extinguishment of debt | 0 | 88 | (457) | 0 | 0 | 0 | 0 | 0 | 0 |
| Loss on acquisitions | 147,376 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in fair value of warrant liability | 90 | 22,678 | (23,463) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (184,462) | (59,335) | 3,387 | (4,040) | (4,367) | (4,510) | (3,949) | (16,866) | (7,561) |
| Preferred dividends | 109 | 103 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net to common | (184,571) | (59,438) | 3,387 | (4,040) | (4,367) | (4,510) | (3,949) | (16,866) | (7,561) |
| Basic Shares | 5,540 | 8,181 | 19,844 | 29,290 | 29,365 | 29,365 | 29,615 | 29,408 | 30,865 |
| Diluted Shares | 5,540 | 8,181 | 22,409 | 29,290 | 29,365 | 29,365 | 29,615 | 29,408 | 30,865 |
| Basic EPS | \$ (33.32) | \$ (7.27) | \$ 0.17 | \$ (0.14) | \$ (0.15) | \$ (0.15) | \$ (0.13) | \$ (0.57) | \$ (0.24) |
| Diluted EPS | \$ (33.32) | \$ (7.27) | \$ 0.15 | \$ (0.14) | \$ (0.15) | \$ (0.15) | \$ (0.13) | \$ (0.57) | \$ (0.24) |
| Depreciation and Amortization | 171 | 1,748 | 1,664 | 409 | 430 | 430 | 430 | 1,699 | 1,647 |
| Stock Comp | 10,280 | 8,940 | 4,140 | 1,091 | 801 | 801 | 801 | 3,494 | 2,400 |
| EBITDA | (29,345) | (16,634) | (11,475) | (2,461) | (3,030) | (3,173) | (2,612) | (11,276) | (3,090) |
| Margin | NM | -39.1% | -24.9% | -14.5% | -18.3% | -23.5% | -17.8% | -18.3% | -3.8% |

Source: Better Choice Company Inc. and Dawson James Securities estimates



Exhibit 2. Balance Sheet and Cash Flow Statement


| | 31-Dec-19 31-Dec-20 | | 31-Dec-21 | | 31-Dec-22 | | 31-Dec-23 | | | |
|----------------------------|---------------------|------------------|-----------|------------------|-----------|-------------------|-----------|----------------|--------|----------|
| (\$ in 000's) | | 2019 | | 2020 | 2021 | | 2022 E | | 2023 E | |
| Cash | \$ | 2,361 | \$ | 3,926 | \$ | 21,729 | \$ | 9,379 | \$ | 2,815 |
| Restricted Cash | | 173 | | 63 | 27.50 | 7,213 | | 6,963 | | 6,963 |
| A/R | | 5,824 | | 4.631 | | 6.792 | | 7,843 | | 10,738 |
| Inventory | | 6,580 | | 4,869 | | 5,245 | | 6,901 | | 9,012 |
| Prepaid expenses and other | | 2,641 | | 4,074 | | 2,940 | | 2,624 | | 3,592 |
| Current Assets | \$ | 17,579 | \$ | 17,563 | \$ | 43,919 | \$ | 33,710 | \$ | 33,119 |
| Current Assets | Ψ | 17,579 | Φ | 17,303 | Φ | 45,515 | Φ | 33,710 | Φ | 33,119 |
| PP&E | | 417 | | 252 | | 369 | | 480 | | 480 |
| Right-of-use assets | | 951 | | 345 | | 56 | | 31 | | 31 |
| Intangible assets | | 14,641 | | 13,115 | | 11,586 | | 10,023 | | 8,496 |
| Goodwill | | 18,614 | | 18,614 | | 18,614 | | 18,614 | | 18,614 |
| Other assets | | 1,330 | | 1,364 | | 116 | | 101 | | 101 |
| Total Assets | \$ | 53,532 | \$ | 51,253 | \$ | 74,660 | \$ | 62,959 | \$ | 60,841 |
| Total Assets | | 33,332 | 9 | 31,233 | φ | 74,000 | | | Φ | |
| Short term loan | \$ | 16,061 | \$ | 7,826 | \$ | 855 | \$ | 1,130 | \$ | 4,996 |
| Line of credit | | 4,819 | | 0 | | 0 | | 0 | | 7,368 |
| PPP loans | | 0 | | 190 | | 0 | | 0 | | 0 |
| Other liabilities | | 500 | | 47 | | 0 | | 0 | | 0 |
| A/P | | 4,049 | | 3,137 | | 4,553 | | 3,564 | | 4,879 |
| Accrued liabilities | | 4,721 | | 3,003 | | 1,879 | | 1,972 | | 2,699 |
| Deferred revenue | | 311 | | 350 | | 0 | | 0 | | 0 |
| Operating lease | | 345 | | 173 | | 54 | | 33 | | 33 |
| Warrant derivative liab. | | 2,220 | | 39,850 | | 0 | | 0 | | 0 |
| Current Liabilities | \$ | 33,026 | \$ | 54,576 | \$ | 7,341 | \$ | 6,699 | \$ | 19,975 |
| N. T. | | 40.070 | | 40.040 | | | | | | |
| Notes payable | | 16,370 | | 18,910 | | 0 | | 0 | | 0 |
| Term loans | | 0 | | 0 | | 4,559 | | 3,866 | | 0 |
| Line of credit | | 0 | | 5,023 | | 4,856 | | 7,368 | | 0 |
| PPP loans | | 0 | | 662 | | 0 | | 0 | | 0 |
| Deferred Tax | | 0 | | 0 | | 24 | | 24 | | 24 |
| Operating lease liab. | | 641 | | 184 | | 5 | | 0 | | 0 |
| Series E Cv. Preferred | | 10,566 | | 0 | | 0 | | 0 | | 0 |
| Total Stockholders' Equity | \$ | (7,071) | \$ | (28,102) | \$ | 57,875 | \$ | 45,003 | \$ | 40,842 |
| Total Liabilities & Equity | \$ | 53,532 | \$ | 51,253 | \$ | 74,660 | \$ | 62,959 | \$ | 60,841 |
| | | | | | | | | | | |
| | 3 | 1-Dec-19 | 3 | 1-Dec-20 | 3 | 1-Dec-21 | 3 | 31-Dec-22 | 3 | 1-Dec-23 |
| | | 2019 | | 2020 | | 2021 | | 2022 E | 1 | 2023 E |
| Net Income | | (184,571) | | (59,438) | | 3,387 | | (16,866) | | (7,561) |
| Depreciation and amort. | | 171 | | 1,748 | | 1,664 | | 1,699 | | 1,647 |
| Share-based comp. | | 10,280 | | 8,940 | | 4,140 | | 3,494 | | 2,400 |
| Working Capital and other | | 153,151 | | 41,245 | | (21,049) | | (3,246) | | (3,931) |
| Operating CF | \$ | (20,969) | \$ | (7,505) | \$ | (11,858) | | (14,919) | | (7,444) |
| Capex | | (110) | | (151) | | (353) | | (249) | | (120) |
| Acquisitions | | (20,097) | | O O | | ° o′ | | O | | 0 |
| Investing Activities | \$ | (20,207) | | (151) | \$ | (353) | \$ | (249) | \$ | (120) |
| Equity | | 20.222 | | 10 101 | | 10 101 | | 500 | | 1.000 |
| Equity | | 20,333 | | 19,101 | | 40,181 | | | | 1,000 |
| Debt Financing | \$ | 19,431 39,764 | \$ | (9,990) 9,111 | \$ | (3,017) 37,164 | \$ | 2,068 2,568 | \$ | 1,000 |
| i manong | Ф | 39,704 | Ф | 9,111 | Φ | 37,104 | Ф | 2,500 | Φ | 1,000 |
| Change in Cash | \$ | (1,412) | \$ | 1,455 | \$ | 24,953 | \$ | (12,600) | \$ | (6,564) |

Source: Better Choice Company Inc. and Dawson James Securities estimates



Important Disclosures:

Price Chart:



Price target and ratings changes over the past three years:

Initiated – Buy – August 31, 2021 – Price Target \$10.00

Update – Buy – October 19, 2021 – Price Target \$10.00

Update - Buy - November 11, 2021 - Price Target \$10.00

Update - Buy - February 11, 2022 - Price Target \$10.00

Update – Buy – March 23, 2022 – Price Target \$10.00

Update – Buy – March 30, 2022 – Price Target \$10.00

Update – Buy – May 13, 2022 – Price Target \$10.00

Update – Buy – July 20, 2022 – Price Target \$10.00

Update - Buy - August 12, 2022 - Price Target \$10.00

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has not received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of August 1, 2022, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.



Information about valuation methods and risks can be found in the "Valuation" and "Risk Analysis" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

- Buy: the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral**: the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell**: the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 8-Aug-22

| | Company | | Investment | |
|----------------------------|----------------|------------|----------------|--------|
| | Coverage | | Banking | % of |
| Ratings Distribution | # of Companies | % of Total | # of Companies | Totals |
| Market Outperform (Buy) | 29 | 66% | 4 | 14% |
| Market Perform (Neutral) | 14 | 32% | 0 | 0% |
| Market Underperform (Sell) | 1 | 2% | 0 | 0% |
| Total | 44 | 100% | 4 | 9% |

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.